BioCentury | Jul 31, 2020
Distillery Therapeutics

Oral small molecule viral RNA polymerase inhibitor for parainfluenza virus

DISEASE CATEGORY: Infectious disease INDICATION: Parainfluenza virus (PIV) An isoquinolylbenzamide-based inhibitor of viral RNA-dependent RNA polymerase could treat infections by PIV and other paramyxoviruses. Cell-based high-throughput screens of 141,936 small molecules yielded an isoquinolylbenzamide-based compound,...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Vesicular trafficking protein fusion targets for metastatic osteosarcoma

DISEASE CATEGORY: Cancer INDICATION: Bone cancer Interrupting the interaction between RAP1GDS1, which can regulate cell migration, and vesicle trafficking protein RAB22A fusions could treat metastatic osteosarcoma bearing the mutations. The RAB22A fusion proteins are caused...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer The antimalarial drug lumefantrine, an FLI1 inhibitor, could treat glioblastoma resistant to radiation and temozolomide. A cell-based screen of compounds structurally related to approved and unapproved treatments for Ewing...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

Fudan University develops pan-coronavirus inhibitor A team led by Fudan University researchers has developed a lipopeptide-based pan-coronavirus inhibitor of viral membrane fusion. Described in a preprint on the bioRxiv server, the lipopeptide binds the SARS-CoV-2...
BioCentury | Oct 31, 2019

Allosteric inhibitor of PGAM1 identified for NSCLC

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) A benzenesulfonamide-based allosteric inhibitor of PGAM1, given alone or in combination with the EGFR inhibitor Tarceva erlotinib, could treat NSCLC. Structure-based optimization of a previously reported...
BioCentury | Oct 17, 2019

Small molecule disruption of Hsp90-CDC37 interaction for colorectal cancer

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer A small molecule inhibiting the interaction between the stress response protein Hsp90 and its co-chaperone CDC37 could treat colorectal cancer. In silico docking studies of a small molecule library...
BioCentury | Feb 7, 2019
Tools & Techniques

Virtual compound library for high throughput computational drug discovery

University of California San Francisco researchers have launched an updated, publicly available and growing virtual library of over 350 million small molecules, all of which can be synthesized on demand. Combined with high throughput computational...
BioCentury | Jan 29, 2019
Distillery Techniques

Drug platforms; other

TECHNOLOGY: Antibody scaffolds; computational models A method of optimizing antibodies for broad activity against different viral strains could be used to generate antibodies to treat infections by influenza and other multi-strain viruses. The method is...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies identified a pyrimidinone-based inhibitor of TLR4 that could help treat MI. Chemical synthesis and screening of peptidomimetic analogs of a previously identified TLR4 inhibitor peptide in...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Cell culture, mouse and rat studies identified an RSV F protein inhibitor that could help treat RSV infection. Optimization and testing in HeLa cell-based assays of a previously reported quinoline-based...
Items per page:
1 - 10 of 130